TY - JOUR
T1 - Patterns of care in the management of high-risk COPD in Australia (2015–2019)
T2 - an observational study for the CONQUEST quality improvement program
AU - Jenkins, Christine
AU - Dickens, Andrew P.
AU - Evans, Alexander
AU - Le Cheng, Porsche
AU - Heraud, Florian
AU - Hancock, Kerry
AU - Sharma, Anita
AU - Cochrane, Belinda
AU - Roussos, Alexander
AU - Le Lievre, Chantal
AU - Blakey, John
AU - Bosnic-Anticevich, Sinthia
AU - Carter, Victoria
AU - Catanzariti, Angelina
AU - Ghisla, Clare
AU - Hew, Mark
AU - Ko, Brian
AU - Le, Thao
AU - Leong, Paul
AU - McDonald, Vanessa M.
AU - Lau, Chi Ming
AU - Perret, Jennifer L.
AU - Pullen, Rachel
AU - Ranasinghe, Kanchanamala
AU - Soriano, Joan B.
AU - Stewart, Deb
AU - van Melle, Marije
AU - Wiseman, Russell
AU - Price, David
N1 - Publisher Copyright:
© 2025 The Author(s)
PY - 2025/5
Y1 - 2025/5
N2 - Background: We compared the management of patients with ‘high-risk’ COPD in Australia to national/international guidelines and quality standards, including the COllaboratioN on QUality improvement initiative for achieving Excellence in STandards of COPD care (CONQUEST). Methods: Eligible patients in the Optimum Patient Care Research Database Australia were categorized as newly diagnosed (≤12 months after diagnosis), already diagnosed, or patients with potential undiagnosed COPD, in each year from 2015 to 2019. ‘High-risk’ patients had ≥2 COPD exacerbations/exacerbation-like events in the last 24 months. Descriptive statistics for 2019 are reported, along with annual trends. Findings: In 2019, 11.3% (2608/22,985) of eligible patients met high-risk criteria. Most newly diagnosed high-risk COPD patients (71.3%) had no recorded lung function testing within 12 months of diagnosis. 63.6% of new COPD diagnoses had no evidence of supporting spirometry or chest CT, with the remainder having recorded chest CT only. 44.3% of already diagnosed high-risk patients had no recorded inhaled maintenance therapy, although this was recorded for 11.2% of potential undiagnosed patients. Smoking cessation support and pulmonary rehabilitation were recorded for <40% and ≤2% of diagnosed COPD patients respectively. Interpretation: There is substantial opportunity to improve diagnosis, assessment and treatment of patients with COPD in Australia by identifying, reviewing and managing high-risk patients in accordance with evidence-based guidelines and CONQUEST standards. Funding: This study was conducted by Optimum Patient Care Australia Pty Ltd (OPCA) and was partially funded by OPCA and AstraZeneca Pty Ltd. No funding was received by the Observational & Pragmatic Research Institute Pte Ltd (OPRI) for its contribution.
AB - Background: We compared the management of patients with ‘high-risk’ COPD in Australia to national/international guidelines and quality standards, including the COllaboratioN on QUality improvement initiative for achieving Excellence in STandards of COPD care (CONQUEST). Methods: Eligible patients in the Optimum Patient Care Research Database Australia were categorized as newly diagnosed (≤12 months after diagnosis), already diagnosed, or patients with potential undiagnosed COPD, in each year from 2015 to 2019. ‘High-risk’ patients had ≥2 COPD exacerbations/exacerbation-like events in the last 24 months. Descriptive statistics for 2019 are reported, along with annual trends. Findings: In 2019, 11.3% (2608/22,985) of eligible patients met high-risk criteria. Most newly diagnosed high-risk COPD patients (71.3%) had no recorded lung function testing within 12 months of diagnosis. 63.6% of new COPD diagnoses had no evidence of supporting spirometry or chest CT, with the remainder having recorded chest CT only. 44.3% of already diagnosed high-risk patients had no recorded inhaled maintenance therapy, although this was recorded for 11.2% of potential undiagnosed patients. Smoking cessation support and pulmonary rehabilitation were recorded for <40% and ≤2% of diagnosed COPD patients respectively. Interpretation: There is substantial opportunity to improve diagnosis, assessment and treatment of patients with COPD in Australia by identifying, reviewing and managing high-risk patients in accordance with evidence-based guidelines and CONQUEST standards. Funding: This study was conducted by Optimum Patient Care Australia Pty Ltd (OPCA) and was partially funded by OPCA and AstraZeneca Pty Ltd. No funding was received by the Observational & Pragmatic Research Institute Pte Ltd (OPRI) for its contribution.
KW - Australia
KW - Coordination of care
KW - COPD
KW - Diagnosis
KW - Exacerbations
KW - Spirometry
KW - Treatment
UR - https://www.scopus.com/pages/publications/105004293027
U2 - 10.1016/j.lanwpc.2025.101555
DO - 10.1016/j.lanwpc.2025.101555
M3 - Article
AN - SCOPUS:105004293027
SN - 2666-6065
VL - 58
JO - The Lancet Regional Health - Western Pacific
JF - The Lancet Regional Health - Western Pacific
M1 - 101555
ER -